A retrospective study to assess the impact of dose reductions on outcomes in CLL patients treated with ibrutinib in a real-world setting
Latest Information Update: 13 Aug 2020
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 13 Aug 2020 New trial record